Triethylamine → 2-amino-6-fluoro-N-(5-fluoro-4-(4-((tetrahydro-2H-pyran-4-yl)sulfonyl)piperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
反応式
[O:1]1[CH2:6][CH2:5][CH:4]([S:7](Cl)(=[O:9])=[O:8])[CH2:3][CH2:2]1.[NH2:11][C:12]1[C:21]([C:22]([NH:24][C:25]2[CH:26]=[N:27][CH:28]=[C:29]([F:37])[C:30]=2[N:31]2[CH2:36][CH2:35][NH:34][CH2:33][CH2:32]2)=[O:23])=[C:15]2[N:16]=[CH:17][C:18]([F:20])=[CH:19][N:14]2[N:13]=1.CCN(CC)CC>CN(C=O)C>[NH2:11][C:12]1[C:21]([C:22]([NH:24][C:25]2[CH:26]=[N:27][CH:28]=[C:29]([F:37])[C:30]=2[N:31]2[CH2:36][CH2:35][N:34]([S:7]([CH:4]3[CH2:5][CH2:6][O:1][CH2:2][CH2:3]3)(=[O:9])=[O:8])[CH2:33][CH2:32]2)=[O:23])=[C:15]2[N:16]=[CH:17][C:18]([F:20])=[CH:19][N:14]2[N:13]=1参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
Tetrahydropyran-4-sulfonyl chloride (16.28 mg, 0.08815 mmol) was added to a suspension of 2-amino-6-fluoro-N-(5-fluoro-4-piperazin-1-yl-3-pyridyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (30 mg, 0.08014 mmol) (synthesized according to the procedure similar to Example 2) and Et3N (12.16 mg, 16.75 μL, 0.1202 mmol) in DMF (0.2 mL). The crude mixture was purified by Fractionlynx HPLC. The clean aqueous fractions were combined and lyophilised, yielding 2-amino-6-fluoro-N-(5-fluoro-4-(4-((tetrahydro-2H-pyran-4-yl)sulfonyl)piperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide. MS (ES+) 523.1.
後処理
- customsynthesized
- customThe crude mixture was purified by Fractionlynx HPLC
出典と根拠
- ORDレコード
- ord-d8aeed86df614bb0861c85afc113320d
- 出典データセット
- uspto-grants-2016_05
- 特許番号
- US09340546B2
反応ノート
読み込み中…